Clinical Trial Update: A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and pharmacodynamic efficacy of 0382 in adults with NAFLD/NASH has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• 0382

Snippet

Sponsor: MedImmune LLC | Conditions: Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2022-05-31